MYD88 and acute kidney injury: Our study also identifies DAPK1 as a putative therapeutic target for septic AKI and demonstrates that pharmacological deactivation or genetic ablation of DAPK1 in combination with MyD88 inhibitor provides better efficacy against septic AKI.